Fredun Pharma investors face last chance for 2:1 bonus
Today marks the final trading day for investors to buy Fredun Pharmaceuticals shares to qualify for the company's 2:1 bonus issue, a corporate move capping off a 200% annual rally driven by diversification into higher-value segments.
Today is the final trading day for investors to buy Fredun Pharmaceuticals shares and qualify for the company's 2:1 bonus issue, with the record date set for Thursday. Under India's T+1 settlement cycle, shares must be credited to a buyer's demat account by the end of the prior trading session to capture the corporate action. This makes Wednesday the critical cut-off for market participants.
Eligible shareholders will receive two bonus shares, each with a face value of Rs 10, for every one share held. The company announced the move in May, stating the strategic intent was to reward shareholders for their long-term commitment and signal management's confidence in structural earnings growth. The microcap currently holds a market capitalisation of more than Rs 1,559 crore.
The stock has seen a sharp run-up ahead of the ex-date, gaining 8% over the past five days and 22% over the past month. Shares were trading around Rs 2,820 on Wednesday morning after a slight dip of over 1%. These recent gains build on a much broader rally, with the stock up 84% so far in 2026 and nearly 200% over the past 12 months. Over a five-year horizon, Fredun Pharma has delivered a 590% return.
For market professionals, the significance of the bonus issue lies in management's explicit signaling of future earnings. Fredun Medhora, Managing Director, positioned the move as a reflection of structural growth and long-term scalability.
"The recommendation of a 2:1 bonus issue reflects the strong momentum we have built and our confidence in sustaining this growth trajectory," Medhora said.
Management tied this confidence to robust performance across both revenue and profitability. A key driver of this momentum is the company's ongoing diversification strategy. Medhora highlighted continued progress in expanding into higher-value segments, specifically nutraceuticals, cosmeceuticals, and pet healthcare. The company stated these moves are intended to strengthen the quality and scalability of the business to support consistent, long-term value creation.
